Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aravive Inc

Current price
Last closed 0.04 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 949 860 USD
Yield for 12 month -100.00 %
21.11.2021 - 28.11.2021

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas. Address: River Oaks Tower, Houston, TX, United States, 77098

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

0.25 USD

P/E ratio

Dividend Yield

Current Year

+6 994 000 USD

Last Year

+9 137 000 USD

Current Quarter

+2 756 000 USD

Last Quarter

+1 274 000 USD

Current Year

Last Year

+9 137 000 USD

Current Quarter

-5 974 000 USD

Last Quarter

-9 516 000 USD

Key Figures ARAV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -58 398 000 USD
Operating Margin TTM -323.44 %
PE Ratio
Return On Assets TTM -134.06 %
PEG Ratio
Return On Equity TTM -475.98 %
Wall Street Target Price 0.25 USD
Revenue TTM 6 994 000 USD
Book Value 0.023 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -44.4 %
Dividend Yield
Gross Profit TTM -57 801 000 USD
Earnings per share -0.76 USD
Diluted Eps TTM -0.76 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ARAV

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARAV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:6
Payout Ratio
Last Split Date 16.10.2018
Dividend Date 16.10.2018

Stock Valuation ARAV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.2763
Price Sales TTM 0.4218
Enterprise Value EBITDA 0.0541
Price Book MRQ 1.7342

Financials ARAV

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ARAV

For 52 weeks

0.04 USD 1.84 USD
50 Day MA 0.1 USD
Shares Short Prior Month 1 401 253
200 Day MA 0.59 USD
Short Ratio 0.91
Shares Short 1 330 622
Short Percent 2.94 %

Dynamics of changes in the value of assets



0.015 USD Westmount Energy Limited 0 (0%)
Detailed analytics


0.069 AUD Osmond Resources Ltd 0 (0%)
Detailed analytics


0.0010 EUR Metalicity Limited 0 (0%)
Detailed analytics


0.87 USD Power REIT -0.06 (-6.04%)
Detailed analytics


0.023 USD Nevada Sunrise Gold Corporation 0 (0%)
Detailed analytics